Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
WALTHAM, Mass., Nov. 16, 2016 -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced a public offering of $175,000,000 of its American Depositary Shares ("ADSs"), each representing 13 of its ordinary shares, par value $0.0001 per share. BeiGene is proposing to sell $160,000,000 of its ADSs, and certain selling stockholders are proposing to sell $15,000,000 of BeiGene ADSs. In addition, the underwriters have been granted a 30-day option to purchase up to an additional $26,250,000 of ADSs from BeiGene.
Morgan Stanley, Goldman, Sachs & Co. and Cowen and Company are acting as joint book-running managers.
The offering will be made only by means of a prospectus, copies of which may be obtained for free from the offices of Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, or email: [email protected]; or Cowen and Company, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, United States, Attn.: Prospectus Department or by calling +1 (631) 274 2806.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. A registration statement relating to these securities was filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.
Investor/Media Contact Lucy Li, Ph.D. +1 781-801-1800 [email protected] [email protected]
